India is ready to invest in Eastern Europe’s pharmaceutical industry

According to Manoj Kumar Bharti, Ambassador Extraordinary and Plenipotentiary of India to Belarus, India companies are ready to invest in pharmaceutical production in Belarus. India has world renowned capacity in producing low cost, high quality bulk and generic drugs. Supply of such drugs and investment in producing pharmaceutical products in Belarus through JV by Indian companies will provide win-win situation for both countries. Presently $700 million …

Biotechs to save Asia from Ebola

Asian Scientist Magazine had recently questioned what Asia’s best bet would be should Ebola reach the largest and most populated continent. The biggest barrier to pandemic preparedness has always been the novelty of the disease. When SARS (severe acute respiratory syndrome) had first hit Asia, it reached almost 40 countries within weeks through air-borne respiratory emissions from Hong Kong. However, …

Changing the image of Asia pharmaceutical industry

Asia is producing young, exciting R&D specialists, large manufacturing plants and copius amounts of patient data. However, it has always been considered a developing continent with “Copy cat” reputation. Recently, Greencross, a Korean pharmaceuticals have produced Hepavax, a Hepatitis B Vaccine which vaccinated over 130 million people. It has also developed the first epidemic hemorragic fever vaccine, a chicken pox …

Spotlight back on Antibiotics Market

Thought to be undervalued and overshadowed by the bigger revenue draw from blockbuster drug manufacturing, Merck’s ($MRK) recent acquisition of Cubist ($CBST) might have placed a spotlight back to the Antibiotics Market. Unlike its compatriots in the biologic therapeutics market, antibiotics target specifically on bacterial infections. More often than not, the efficacy of antibiotics decreases through the misuse of antibiotics. …

New Age Project Management

Traditionally, Project Management was all about cost, timeline and success of that project. But most often than not, there are dependencies for a project – either upstream or downstream. These dependencies become all the more important when (mostly when and not if) the project deviates from cost ortimeline. On what basis should the decision makers tasked with bringing back the project on track make these …

investment in cell therapies

Promising scale and market success for cell therapies after large financial injection

In a report released this week, by BCC Research, it was forecasted that the global market for stem cells (including cell therapies) is to reach US $10.6 billion in 2018. However with currently no medicines, based on stem cells, having yet received marketing authorisation from the EMA*, or the FDA*, how are we going to get there? In 2013, the stem cell …

An investor perspective and analysis of the stem cell & regenerative medicine sector

Dr. Navid Malik B.Sc. M.Sc. MBA, Cenkos joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘An investor perspective and analysis of the stem cell & regenerative medicine sector’ Download this presentation now to find out: Cenkos Securities’ focus on Life Sciences Longer-term sector returns have been very positive Significant opportunity to generate …

Acquisition: advantages and strategies available

Michael West, Chief Executive Officer, BioTime joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Acquisition Strategies.’ Download this presentation now to find out: Pluripotent Stem Cells Two Defining Characteristics of hESCs OPC1–Oligodendrocyte Progenitor Cells Telomerase Cancer Vaccine HyStem Hydrogels –Competitive Advantages Background on BioTime Acquisition Deal Points ..and much more! Get your copy …